Trial Profile
A Prospective, Open-label, Non-comparative Study To Assess The Safety, Tolerability And Efficacy Of Voriconazole For The Primary And Salvage Treatment Of Invasive Candidiasis, Candidemia, And Esophageal Candidiasis In Pediatric Subjects
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs Voriconazole (Primary)
- Indications Candidaemia; Candidiasis; Invasive candidiasis
- Focus Adverse reactions
- Sponsors Pfizer
- 11 Jan 2022 This trial has been completed in Romania (End Date: 08 Jul 2012), according to European Clinical Trials Database record.
- 15 Sep 2016 Results (n=53) assessing safety and efficacy outcomes of Voriconzaole in pediatric patients from NCT01092832 and NCT00836875 studies, published in the Pediatric Infectious Disease Journal.
- 19 Jan 2015 New trial record